<div class="xtend"><a id="pl.1.1"></a><var>1.1</var>CONFERENCE COMMITTEE REPORT ON S.F. No. 651<br />
         		
         <div class="xtend_ce"><a id="pl.1.2"></a><var>1.2</var>A bill for an act<br />
            		
         </div><a id="pl.1.3"></a><var>1.3</var>relating to the environment; restricting the manufacture and sale of certain <br />
         		<a id="pl.1.4"></a><var>1.4</var>polybrominated diphenyl ethers; requiring a report; providing penalties;<br />
         		<a id="pl.1.5"></a><var>1.5</var>amending Minnesota Statutes 2007 Supplement, sections 325E.386; 325E.387, <br />
         		<a id="pl.1.6"></a><var>1.6</var>by adding a subdivision.<br />
         		<a id="pl.1.7"></a><var>1.7</var>May 6, 2008<br />
         		<a id="pl.1.8"></a><var>1.8</var>The Honorable James P. Metzen<br />
         		<a id="pl.1.9"></a><var>1.9</var>President of the Senate<br />
         		<a id="pl.1.10"></a><var>1.10</var>The Honorable Margaret Anderson Kelliher<br />
         		<a id="pl.1.11"></a><var>1.11</var>Speaker of the House of Representatives<br />
         		<a id="pl.1.12"></a><var>1.12</var>We, the undersigned conferees for S.F. No. 651 report that we have agreed upon the <br />
         		<a id="pl.1.13"></a><var>1.13</var>items in dispute and recommend as follows:<br />
         		<a id="pl.1.14"></a><var>1.14</var>That the House recede from its amendment and that S.F. No. 651 be further amended <br />
         		<a id="pl.1.15"></a><var>1.15</var>as follows:<br />
         		<a id="pl.1.16"></a><var>1.16</var>Delete everything after the enacting clause and insert:<br />
         		<br />
         		<a id="bill.0.1.0"></a><a id="pl.1.17"></a><var>1.17</var>&nbsp;&nbsp;&nbsp;&nbsp;"Section 1. Minnesota Statutes 2007 Supplement, section 144.651, subdivision 9, <br />
         		<a id="pl.1.18"></a><var>1.18</var>is amended to read:<br />
         		<a id="pl.1.19"></a><var>1.19</var>&nbsp;&nbsp;&nbsp;&nbsp;Subd. 9. <b>Information about treatment.</b> (a) Patients and residents shall be given by <br />
         		<a id="pl.1.20"></a><var>1.20</var>their physicians complete and current information concerning their diagnosis, treatment, <br />
         		<a id="pl.1.21"></a><var>1.21</var>alternatives, risks, and prognosis as required by the physician's legal duty to disclose. This <br />
         		<a id="pl.1.22"></a><var>1.22</var>information shall be in terms and language the patients or residents can reasonably be <br />
         		<a id="pl.1.23"></a><var>1.23</var>expected to understand. Patients and residents may be accompanied by a family member <br />
         		<a id="pl.1.24"></a><var>1.24</var>or other chosen representative, or both. This information shall include the likely medical <br />
         		<a id="pl.1.25"></a><var>1.25</var>or major psychological results of the treatment and its alternatives. In cases where it is <br />
         		<a id="pl.1.26"></a><var>1.26</var>medically inadvisable, as documented by the attending physician in a patient's or resident's <br />
         		<a id="pl.1.27"></a><var>1.27</var>medical record, the information shall be given to the patient's or resident's guardian or <br />
         		<a id="pl.1.28"></a><var>1.28</var>other person designated by the patient or resident as a representative. Individuals have the <br />
         		<a id="pl.1.29"></a><var>1.29</var>right to refuse this information.<br />
         		<a id="pl.2.1"></a><var>2.1</var>&nbsp;&nbsp;&nbsp;&nbsp;(b) Every patient or resident suffering from any form of breast cancer shall be fully <br />
         		<a id="pl.2.2"></a><var>2.2</var>informed, prior to or at the time of admission and during her stay, of all alternative <br />
         		<a id="pl.2.3"></a><var>2.3</var>effective methods of treatment of which the treating physician is knowledgeable, including <br />
         		<a id="pl.2.4"></a><var>2.4</var>surgical, radiological, or chemotherapeutic treatments or combinations of treatments and <br />
         		<a id="pl.2.5"></a><var>2.5</var>the risks associated with each of those methods.<br />
         		<a id="pl.2.6"></a><var>2.6</var>&nbsp;&nbsp;&nbsp;&nbsp;(c) Every patient receiving maternity care has the right to continuous support from a <br />
         		<a id="pl.2.7"></a><var>2.7</var>doula of her choice, in addition to her family, during her stay at the facility, so long as <br />
         		<a id="pl.2.8"></a><var>2.8</var>the doula performs doula services within an accepted scope of practice and the hospital's <br />
         		<a id="pl.2.9"></a><var>2.9</var>standard of care. Nothing in this paragraph prohibits or restricts a hospital from excluding <br />
         		<a id="pl.2.10"></a><var>2.10</var>a doula who has violated an accepted scope of practice or the hospital's standard of care.<br />
         		<br />
         		<a id="bill.0.2.0"></a><a id="pl.2.11"></a><var>2.11</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 2. <b>[145.907] PAIN RELIEF INFORMATION FOR PREGNANT PATIENTS.</b><br />
         		<a id="pl.2.12"></a><var>2.12</var>&nbsp;&nbsp;&nbsp;&nbsp;Physicians, traditional midwives, and other licensed health care professionals <br />
         		<a id="pl.2.13"></a><var>2.13</var>providing prenatal care to women must include as part of their prenatal education, <br />
         		<a id="pl.2.14"></a><var>2.14</var>information regarding all methods of pain relief, including evidence-based <br />
         		<a id="pl.2.15"></a><var>2.15</var>nonpharmacological methods.<br />
         		<br />
         		<a id="bill.0.3.0"></a><a id="pl.2.16"></a><var>2.16</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 3. Minnesota Statutes 2007 Supplement, section 325E.386, is amended to read:<br />
         		<a id="pl.2.17"></a><var>2.17</var><b>325E.386 PRODUCTS CONTAINING CERTAIN POLYBROMINATED </b><br />
         		<a id="pl.2.18"></a><var>2.18</var><b>DIPHENYL ETHERS BANNED; EXEMPTIONS.</b><br />
         		<a id="pl.2.19"></a><var>2.19</var>&nbsp;&nbsp;&nbsp;&nbsp;Subdivision 1. <b>Penta- and octabromodiphenyl ethers.</b> Except as provided in <br />
         		<a id="pl.2.20"></a><var>2.20</var>subdivision 3 2, beginning January 1, 2008, a person may not manufacture, process, or <br />
         		<a id="pl.2.21"></a><var>2.21</var>distribute in commerce a product or flame-retardant part of a product containing more <br />
         		<a id="pl.2.22"></a><var>2.22</var>than one-tenth of one percent of pentabromodiphenyl ether or octabromodiphenyl ether <br />
         		<a id="pl.2.23"></a><var>2.23</var>by mass.<br />
         		<a id="pl.2.24"></a><var>2.24</var>&nbsp;&nbsp;&nbsp;&nbsp;Subd. 2. <b>Exemptions</b><b>; penta- and octabromodiphenyl ethers</b><b>.</b> The following <br />
         		<a id="pl.2.25"></a><var>2.25</var>products containing polybrominated diphenyl ethers are exempt from subdivision 1 and <br />
         		<a id="pl.2.26"></a><var>2.26</var>section 
         <statute_ref>325E.387, subdivision 2</statute_ref>:<br />
         		<a id="pl.2.27"></a><var>2.27</var>&nbsp;&nbsp;&nbsp;&nbsp;(1) the sale or distribution of any used transportation vehicle with component parts <br />
         		<a id="pl.2.28"></a><var>2.28</var>containing polybrominated diphenyl ethers;<br />
         		<a id="pl.2.29"></a><var>2.29</var>&nbsp;&nbsp;&nbsp;&nbsp;(2) the sale or distribution of any used transportation vehicle parts or new <br />
         		<a id="pl.2.30"></a><var>2.30</var>transportation vehicle parts manufactured before January 1, 2008, that contain <br />
         		<a id="pl.2.31"></a><var>2.31</var>polybrominated diphenyl ethers;<br />
         		<a id="pl.2.32"></a><var>2.32</var>&nbsp;&nbsp;&nbsp;&nbsp;(3) the manufacture, sale, repair, distribution, maintenance, refurbishment, or <br />
         		<a id="pl.2.33"></a><var>2.33</var>modification of equipment containing polybrominated diphenyl ethers and used primarily <br />
         		<a id="pl.2.34"></a><var>2.34</var>for military or federally funded space program applications. This exemption does not <br />
         		<a id="pl.2.35"></a><var>2.35</var>cover consumer-based goods with broad applicability;<br />
         		<a id="pl.3.1"></a><var>3.1</var>&nbsp;&nbsp;&nbsp;&nbsp;(4) the sale or distribution by a business, charity, public entity, or private party of <br />
         		<a id="pl.3.2"></a><var>3.2</var>any used product containing polybrominated diphenyl ethers;<br />
         		<a id="pl.3.3"></a><var>3.3</var>&nbsp;&nbsp;&nbsp;&nbsp;(5) the manufacture, sale, or distribution of new carpet cushion made from recycled <br />
         		<a id="pl.3.4"></a><var>3.4</var>foam containing more than one-tenth of one percent polybrominated diphenyl ether; <br />
         		<a id="pl.3.5"></a><var>3.5</var>&nbsp;&nbsp;&nbsp;&nbsp;(6) medical devices; or<br />
         		<a id="pl.3.6"></a><var>3.6</var>&nbsp;&nbsp;&nbsp;&nbsp;(7) the manufacture, sale, repair, distribution, maintenance, refurbishment, or <br />
         		<a id="pl.3.7"></a><var>3.7</var>modification of telecommunications equipment containing polybrominated diphenyl <br />
         		<a id="pl.3.8"></a><var>3.8</var>ethers used by entities eligible to hold authorization in the Public Safety Pool under Code <br />
         		<a id="pl.3.9"></a><var>3.9</var>of Federal Regulations, title 47, part 90.<br />
         		<a id="pl.3.10"></a><var>3.10</var>&nbsp;&nbsp;&nbsp;&nbsp;In-state retailers in possession of products on January 1, 2008, that are banned for <br />
         		<a id="pl.3.11"></a><var>3.11</var>sale under subdivision 1 may exhaust their stock through sales to the public. Nothing in <br />
         		<a id="pl.3.12"></a><var>3.12</var>this section restricts the ability of a manufacturer, importer, or distributor  from transporting <br />
         		<a id="pl.3.13"></a><var>3.13</var>products containing polybrominated diphenyl ethers through the state,  or storing such <br />
         		<a id="pl.3.14"></a><var>3.14</var>products in the state for later distribution outside the state.<br />
         		<a id="pl.3.15"></a><var>3.15</var>&nbsp;&nbsp;&nbsp;&nbsp;Subd. 3. <b>Commercial decabromodiphenyl ether.</b> (a) Except as provided in <br />
         		<a id="pl.3.16"></a><var>3.16</var>subdivision 4, beginning July 1, 2011, a person may not manufacture, process, or distribute <br />
         		<a id="pl.3.17"></a><var>3.17</var>in commerce any of the following products containing more than one-tenth of one percent <br />
         		<a id="pl.3.18"></a><var>3.18</var>of commercial decabromodiphenyl ether by mass:<br />
         		<a id="pl.3.19"></a><var>3.19</var>&nbsp;&nbsp;&nbsp;&nbsp;(1) the exterior casing of a television, computer, or computer monitor;<br />
         		<a id="pl.3.20"></a><var>3.20</var>&nbsp;&nbsp;&nbsp;&nbsp;(2) upholstered furniture or textiles intended for indoor use in a home or other <br />
         		<a id="pl.3.21"></a><var>3.21</var>residential occupancy; or<br />
         		<a id="pl.3.22"></a><var>3.22</var>&nbsp;&nbsp;&nbsp;&nbsp;(3) mattresses and mattress pads.<br />
         		<a id="pl.3.23"></a><var>3.23</var>&nbsp;&nbsp;&nbsp;&nbsp;(b) The sale or distribution by a business, charity, public entity, or private party of <br />
         		<a id="pl.3.24"></a><var>3.24</var>any used product containing commercial decabromodiphenyl ether is exempted from <br />
         		<a id="pl.3.25"></a><var>3.25</var>this subdivision.<br />
         		<a id="pl.3.26"></a><var>3.26</var>&nbsp;&nbsp;&nbsp;&nbsp;(c) In-state retailers in possession of products on January 1, 2011, that are banned for <br />
         		<a id="pl.3.27"></a><var>3.27</var>sale under this subdivision may exhaust their stock of products located in the state as of that <br />
         		<a id="pl.3.28"></a><var>3.28</var>date through sales to the public. Nothing in this section restricts a manufacturer, importer, <br />
         		<a id="pl.3.29"></a><var>3.29</var>or distributor from transporting products containing commercial decabromodiphenyl ether <br />
         		<a id="pl.3.30"></a><var>3.30</var>through the state or storing such products in the state for later distribution outside the state.<br />
         		<a id="pl.3.31"></a><var>3.31</var>&nbsp;&nbsp;&nbsp;&nbsp;Subd. 4. <b>Exemption process; commercial decabromodiphenyl ether.</b> (a) A <br />
         		<a id="pl.3.32"></a><var>3.32</var>manufacturer or user of a product prohibited from manufacture, sale, or distribution <br />
         		<a id="pl.3.33"></a><var>3.33</var>under subdivision 3 may apply for an exemption for a specific use of commercial <br />
         		<a id="pl.3.34"></a><var>3.34</var>decabromodiphenyl ether under this section by filing a written request with the <br />
         		<a id="pl.3.35"></a><var>3.35</var>commissioner. The commissioner may grant an exemption for a term not to exceed three <br />
         		<a id="pl.4.1"></a><var>4.1</var>years. The exemption is renewable upon written request. An initial or renewal request for <br />
         		<a id="pl.4.2"></a><var>4.2</var>exemption must include at least the following:<br />
         		<a id="pl.4.3"></a><var>4.3</var>&nbsp;&nbsp;&nbsp;&nbsp;(1) a policy statement articulating upper management support for eliminating or <br />
         		<a id="pl.4.4"></a><var>4.4</var>reducing to the maximum feasible extent the use of commercial decabromodiphenyl ether;<br />
         		<a id="pl.4.5"></a><var>4.5</var>&nbsp;&nbsp;&nbsp;&nbsp;(2) a description of the product and the amount of commercial decabromodiphenyl <br />
         		<a id="pl.4.6"></a><var>4.6</var>ether distributed for sale and use in the state on an annual basis;<br />
         		<a id="pl.4.7"></a><var>4.7</var>&nbsp;&nbsp;&nbsp;&nbsp;(3) a description of the recycling and disposal system used for the product in the <br />
         		<a id="pl.4.8"></a><var>4.8</var>state and an estimate of the amount of product or commercial decabromodiphenyl ether <br />
         		<a id="pl.4.9"></a><var>4.9</var>that is recycled or disposed of in the state on an annual basis;<br />
         		<a id="pl.4.10"></a><var>4.10</var>&nbsp;&nbsp;&nbsp;&nbsp;(4) a description of the manufacturer's or user's past and ongoing efforts to eliminate <br />
         		<a id="pl.4.11"></a><var>4.11</var>or reduce the amount of commercial decabromodiphenyl ether used in the product;<br />
         		<a id="pl.4.12"></a><var>4.12</var>&nbsp;&nbsp;&nbsp;&nbsp;(5) an assessment of options available to reduce or eliminate the use of commercial <br />
         		<a id="pl.4.13"></a><var>4.13</var>decabromodiphenyl ether, including any alternatives that do not contain commercial <br />
         		<a id="pl.4.14"></a><var>4.14</var>decabromodiphenyl ether, perform the same technical function, are commercially <br />
         		<a id="pl.4.15"></a><var>4.15</var>available, and are economically practicable;<br />
         		<a id="pl.4.16"></a><var>4.16</var>&nbsp;&nbsp;&nbsp;&nbsp;(6) a statement of objectives in numerical terms and a schedule for achieving the <br />
         		<a id="pl.4.17"></a><var>4.17</var>elimination of commercial decabromodiphenyl ether and an environmental assessment of <br />
         		<a id="pl.4.18"></a><var>4.18</var>alternative products, including but not limited to human health, solid waste, hazardous <br />
         		<a id="pl.4.19"></a><var>4.19</var>waste, and wastewater impacts associated with production, use, recycling, and disposal <br />
         		<a id="pl.4.20"></a><var>4.20</var>of the alternatives;<br />
         		<a id="pl.4.21"></a><var>4.21</var>&nbsp;&nbsp;&nbsp;&nbsp;(7) a listing of options considered not to be technically or economically practicable; <br />
         		<a id="pl.4.22"></a><var>4.22</var>and<br />
         		<a id="pl.4.23"></a><var>4.23</var>&nbsp;&nbsp;&nbsp;&nbsp;(8) certification of the accuracy of the information contained in the request, signed <br />
         		<a id="pl.4.24"></a><var>4.24</var>and dated by an official of the manufacturer or user.<br />
         		<a id="pl.4.25"></a><var>4.25</var>&nbsp;&nbsp;&nbsp;&nbsp;(b) The commissioner may grant an initial or renewal exemption for a specific use of <br />
         		<a id="pl.4.26"></a><var>4.26</var>commercial decabromodiphenyl ether, with or without conditions, upon finding that the <br />
         		<a id="pl.4.27"></a><var>4.27</var>applicant has demonstrated that there is no alternative that performs the same technical <br />
         		<a id="pl.4.28"></a><var>4.28</var>function, is commercially available, is economically practicable, and provides net health <br />
         		<a id="pl.4.29"></a><var>4.29</var>and environmental benefits to the state.<br />
         		<a id="pl.4.30"></a><var>4.30</var>&nbsp;&nbsp;&nbsp;&nbsp;Subd. 5. <b>Fees for exemption applicants.</b> The application fee for an exemption <br />
         		<a id="pl.4.31"></a><var>4.31</var>under subdivision 4 is $2,000 per exemption. The fee is exempt from section 16A.1285. <br />
         		<a id="pl.4.32"></a><var>4.32</var>Revenues from application fees must be deposited in the environmental fund.<br />
         		<br />
         		<a id="bill.0.4.0"></a><a id="pl.4.33"></a><var>4.33</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 4. Minnesota Statutes 2007 Supplement, section 325E.387, is amended by adding <br />
         		<a id="pl.4.34"></a><var>4.34</var>a subdivision to read:<br />
         		<a id="pl.5.1"></a><var>5.1</var>&nbsp;&nbsp;&nbsp;&nbsp;Subd. 3. <b>Participation in interstate clearinghouse.</b> The commissioner may <br />
         		<a id="pl.5.2"></a><var>5.2</var>participate in a regional or national multistate clearinghouse to assist in carrying out the <br />
         		<a id="pl.5.3"></a><var>5.3</var>requirements of this section. The clearinghouse is authorized to maintain information on <br />
         		<a id="pl.5.4"></a><var>5.4</var>behalf of Minnesota, including, but not limited to:<br />
         		<a id="pl.5.5"></a><var>5.5</var>&nbsp;&nbsp;&nbsp;&nbsp;(1) a list of all products containing polybrominated diphenyl ethers; and<br />
         		<a id="pl.5.6"></a><var>5.6</var>&nbsp;&nbsp;&nbsp;&nbsp;(2) information on all exemptions granted by the state.<br />
         		<br />
         		<a id="bill.0.5.0"></a><a id="pl.5.7"></a><var>5.7</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 5. <b>[325F.172] DEFINITIONS.</b><br />
         		<a id="pl.5.8"></a><var>5.8</var>&nbsp;&nbsp;&nbsp;&nbsp;For the purposes of sections 325F.172 to 325F.174, the following terms have the <br />
         		<a id="pl.5.9"></a><var>5.9</var>meanings given them.<br />
         		<a id="pl.5.10"></a><var>5.10</var>&nbsp;&nbsp;&nbsp;&nbsp;(a) "BBP" means benzyl butyl phthalate, CAS # 85-68-7.<br />
         		<a id="pl.5.11"></a><var>5.11</var>&nbsp;&nbsp;&nbsp;&nbsp;(b) "Child" means a person under three years of age.<br />
         		<a id="pl.5.12"></a><var>5.12</var>&nbsp;&nbsp;&nbsp;&nbsp;(c) "Children's product" means a product designed or intended by a manufacturer to <br />
         		<a id="pl.5.13"></a><var>5.13</var>be used by a child:<br />
         		<a id="pl.5.14"></a><var>5.14</var>&nbsp;&nbsp;&nbsp;&nbsp;(1) as a toy or an article of clothing;<br />
         		<a id="pl.5.15"></a><var>5.15</var>&nbsp;&nbsp;&nbsp;&nbsp;(2) to facilitate sleep, relaxation, or feeding; or<br />
         		<a id="pl.5.16"></a><var>5.16</var>&nbsp;&nbsp;&nbsp;&nbsp;(3) to be rubbed, poured, sprinkled, sprayed on, introduced into, or otherwise <br />
         		<a id="pl.5.17"></a><var>5.17</var>applied to the human body or any part thereof, including any article used as a component <br />
         		<a id="pl.5.18"></a><var>5.18</var>of such a product.<br />
         		<a id="pl.5.19"></a><var>5.19</var>&nbsp;&nbsp;&nbsp;&nbsp;(d) "DBP" means di-n-butyl phthalate, CAS # 84-74-2.<br />
         		<a id="pl.5.20"></a><var>5.20</var>&nbsp;&nbsp;&nbsp;&nbsp;(e) "DEHP" means di (2-ethylhexyl) phthalate, CAS # 117-81-7.<br />
         		<a id="pl.5.21"></a><var>5.21</var>&nbsp;&nbsp;&nbsp;&nbsp;(f) "DIDP" means di-isodecyl phthalate, CAS # 26761-40-0.<br />
         		<a id="pl.5.22"></a><var>5.22</var>&nbsp;&nbsp;&nbsp;&nbsp;(g) "DINP" means di-iso-nonyl phthalate, CAS # 71549-78-5.<br />
         		<a id="pl.5.23"></a><var>5.23</var>&nbsp;&nbsp;&nbsp;&nbsp;(h) "DNOP" means di-n-octyl phthalate, CAS # 117-84-6.<br />
         		<a id="pl.5.24"></a><var>5.24</var><b>EFFECTIVE DATE.</b>This section is effective the day following final enactment.<br />
         		<br />
         		<a id="bill.0.6.0"></a><a id="pl.5.25"></a><var>5.25</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 6. <b>[325F.173] PHTHALATES IN CHILDREN'S PRODUCTS; BAN.</b><br />
         		<a id="pl.5.26"></a><var>5.26</var>&nbsp;&nbsp;&nbsp;&nbsp;(a) Beginning January 1, 2009, no manufacturer may sell or offer in this state a new <br />
         		<a id="pl.5.27"></a><var>5.27</var>children's product that contains one of the following phthalates: DEHP, DBP, or BBP, in <br />
         		<a id="pl.5.28"></a><var>5.28</var>concentrations exceeding 0.1 percent, including plastic tubing used to deliver a solution <br />
         		<a id="pl.5.29"></a><var>5.29</var>intravenously to a small child.<br />
         		<a id="pl.5.30"></a><var>5.30</var>&nbsp;&nbsp;&nbsp;&nbsp;(b) Beginning January 1, 2009, no manufacturer may sell or offer in this state any <br />
         		<a id="pl.5.31"></a><var>5.31</var>new children's product that can be placed in a child's mouth and contains one of the <br />
         		<a id="pl.5.32"></a><var>5.32</var>following phthalates: DINP, DIDP, or DNOP, in concentrations exceeding 0.1 percent.<br />
         		<a id="pl.5.33"></a><var>5.33</var><b>EFFECTIVE DATE.</b>This section is effective the day following final enactment.<br />
         		<br />
         		<a id="bill.0.7.0"></a><a id="pl.5.34"></a><var>5.34</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 7. <b>[325F.174] REPLACEMENT CHEMICALS.</b><br />
         		<a id="pl.6.1"></a><var>6.1</var>&nbsp;&nbsp;&nbsp;&nbsp;A manufacturer shall not replace phthalates as a result of the prohibition in section <br />
         		<a id="pl.6.2"></a><var>6.2</var>325F.173 with a chemical that is:<br />
         		<a id="pl.6.3"></a><var>6.3</var>&nbsp;&nbsp;&nbsp;&nbsp;(1) classified as "known to be a human carcinogen" or "reasonably anticipated to be <br />
         		<a id="pl.6.4"></a><var>6.4</var>a human carcinogen" in the most recent Report on Carcinogens published by the National <br />
         		<a id="pl.6.5"></a><var>6.5</var>Toxicology Program in the United States Department of Health and Human Services; or<br />
         		<a id="pl.6.6"></a><var>6.6</var>&nbsp;&nbsp;&nbsp;&nbsp;(2) identified by the federal Environmental Protection Agency as causing birth <br />
         		<a id="pl.6.7"></a><var>6.7</var>defects or reproductive or environmental harm.<br />
         		<a id="pl.6.8"></a><var>6.8</var><b>EFFECTIVE DATE.</b>This section is effective the day following final enactment.<br />
         		<br />
         		<a id="bill.0.8.0"></a><a id="pl.6.9"></a><var>6.9</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 8. <b>[325F.175] PARTICIPATION IN INTERSTATE CLEARINGHOUSE.</b><br />
         		<a id="pl.6.10"></a><var>6.10</var>&nbsp;&nbsp;&nbsp;&nbsp;The Minnesota Pollution Control Agency may participate in the establishment and <br />
         		<a id="pl.6.11"></a><var>6.11</var>implementation of a multistate clearinghouse to identify children's products containing <br />
         		<a id="pl.6.12"></a><var>6.12</var>bisphenol-A and phthalates and to evaluate safer alternatives that may be substituted <br />
         		<a id="pl.6.13"></a><var>6.13</var>for those chemicals.<br />
         		<a id="pl.6.14"></a><var>6.14</var><b>EFFECTIVE DATE.</b>This section is effective the day following final enactment.<br />
         		<br />
         		<a id="bill.0.9.0"></a><a id="pl.6.15"></a><var>6.15</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 9. <b>REPORT.</b><br />
         		<a id="pl.6.16"></a><var>6.16</var>&nbsp;&nbsp;&nbsp;&nbsp;(a) By January 15, 2011, the Pollution Control Agency shall report to the senate and <br />
         		<a id="pl.6.17"></a><var>6.17</var>house of representatives committees with jurisdiction over environmental and natural <br />
         		<a id="pl.6.18"></a><var>6.18</var>resources, commerce, public safety, and public health regarding specific flame-retardant <br />
         		<a id="pl.6.19"></a><var>6.19</var>alternatives available for decabromodiphenyl ether.<br />
         		<a id="pl.6.20"></a><var>6.20</var>&nbsp;&nbsp;&nbsp;&nbsp;(b) The Pollution Control Agency shall convene a fire safety committee to <br />
         		<a id="pl.6.21"></a><var>6.21</var>identify and evaluate the safety and effectiveness of flame-retardant alternatives before <br />
         		<a id="pl.6.22"></a><var>6.22</var>decabromodiphenyl ether is phased out. The recommendations of the fire safety committee <br />
         		<a id="pl.6.23"></a><var>6.23</var>shall be incorporated into the report required under paragraph (a).<br />
         		<a id="pl.6.24"></a><var>6.24</var>&nbsp;&nbsp;&nbsp;&nbsp;(c) The fire safety committee consists of the commissioner or designee of the <br />
         		<a id="pl.6.25"></a><var>6.25</var>Pollution Control Agency, as chair and nonvoting member, with the following members:<br />
         		<a id="pl.6.26"></a><var>6.26</var>&nbsp;&nbsp;&nbsp;&nbsp;(1) a representative of the commissioner of health;<br />
         		<a id="pl.6.27"></a><var>6.27</var>&nbsp;&nbsp;&nbsp;&nbsp;(2) a representative of the State Fire Marshal;<br />
         		<a id="pl.6.28"></a><var>6.28</var>&nbsp;&nbsp;&nbsp;&nbsp;(3) a representative appointed by the president of the Minnesota State Fire Chiefs <br />
         		<a id="pl.6.29"></a><var>6.29</var>Association;<br />
         		<a id="pl.6.30"></a><var>6.30</var>&nbsp;&nbsp;&nbsp;&nbsp;(4) a representative appointed by the president of the Minnesota Professional <br />
         		<a id="pl.6.31"></a><var>6.31</var>Firefighters Association;<br />
         		<a id="pl.6.32"></a><var>6.32</var>&nbsp;&nbsp;&nbsp;&nbsp;(5) a representative appointed by the president of the Fire Marshals Association <br />
         		<a id="pl.6.33"></a><var>6.33</var>of Minnesota;<br />
         		<a id="pl.6.34"></a><var>6.34</var>&nbsp;&nbsp;&nbsp;&nbsp;(6) a representative of the Minnesota State Fire Departments Association;<br />
         		<a id="pl.6.35"></a><var>6.35</var>&nbsp;&nbsp;&nbsp;&nbsp;(7) a representative of an environmental health coalition; and<br />
         		<a id="pl.7.1"></a><var>7.1</var>&nbsp;&nbsp;&nbsp;&nbsp;(8) a scientist from the environmental health coalition as a nonvoting member.<br />
         		<br />
         		<a id="bill.0.10.0"></a><a id="pl.7.2"></a><var>7.2</var>&nbsp;&nbsp;&nbsp;&nbsp;Sec. 10. <b>APPROPRIATION.</b><br />
         		<a id="pl.7.3"></a><var>7.3</var>&nbsp;&nbsp;&nbsp;&nbsp;$57,000 is appropriated from the environmental fund to the commissioner of the <br />
         		<a id="pl.7.4"></a><var>7.4</var>Pollution Control Agency for the purposes of sections 3, 4, and 9."<br />
         		<a id="pl.7.5"></a><var>7.5</var>Delete the title and insert:<br />
         		
         <div class="xtend_ce"><a id="pl.7.6"></a><var>7.6</var>"A bill for an act<br />
            		
         </div><a id="pl.7.7"></a><var>7.7</var>relating to health; modifying provisions relating to maternity care; banning the <br />
         		<a id="pl.7.8"></a><var>7.8</var>use of certain phthalates, flame retardants, or other polymers or chemicals; <br />
         		<a id="pl.7.9"></a><var>7.9</var>requiring reports; appropriating money;amending Minnesota Statutes 2007 <br />
         		<a id="pl.7.10"></a><var>7.10</var>Supplement, sections 144.651, subdivision 9; 325E.386; 325E.387, by adding <br />
         		<a id="pl.7.11"></a><var>7.11</var>a subdivision; proposing coding for new law in Minnesota Statutes, chapters <br />
         		<a id="pl.7.12"></a><var>7.12</var>145; 325F."<br />
         		We request the adoption of this report and repassage of the bill.Senate Conferees: (Signed) John Marty, Sandra L. Pappas, Jim Carlson, Patricia Torres Ray, Michelle L. FischbachHouse Conferees: (Signed) Karen Clark, Carolyn Laine, Paul Thissen, Shelley Madore, Jim Abeler
         <table>
            <col width="50px"></col>
            <col width="252px"></col>
            <col width="42px"></col>
            <col width="252px"></col>
            <tr>
               <td><a id="pl.8.1"></a><var>8.1</var><br />
                  		
               </td>
               <td colspan="3" align="left" valign="bottom">We request the adoption of this report and repassage of the bill.<br />
                  		
               </td>
            </tr>
            <tr>
               <td><a id="pl.8.2"></a><var>8.2</var><br />
                  		
               </td>
               <td align="left" valign="bottom">Senate Conferees:<span width="2em"></span>(Signed)<br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom"></td>
            </tr>
            <tr>
               <td><a id="pl.8.3"></a><var>8.3</var><br />
                  		
               </td>
               <td align="left" valign="bottom"><span>
                     							.....
                     						</span><br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom"><span>
                     							.....
                     						</span><br />
                  		
               </td>
            </tr>
            <tr>
               <td><a id="pl.8.4"></a><var>8.4</var><br />
                  		
               </td>
               <td align="left" valign="bottom">John Marty<br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom">Sandra L. Pappas<br />
                  		
               </td>
            </tr>
            <tr>
               <td><a id="pl.8.5"></a><var>8.5</var><br />
                  		
               </td>
               <td align="left" valign="bottom"><span>
                     							.....
                     						</span><br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom"><span>
                     							.....
                     						</span><br />
                  		
               </td>
            </tr>
            <tr>
               <td><a id="pl.8.6"></a><var>8.6</var><br />
                  		
               </td>
               <td align="left" valign="bottom">Jim Carlson<br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom">Patricia Torres Ray<br />
                  		
               </td>
            </tr>
            <tr>
               <td><a id="pl.8.7"></a><var>8.7</var><br />
                  		
               </td>
               <td align="left" valign="bottom"><span>
                     							.....
                     						</span><br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom"></td>
            </tr>
            <tr>
               <td><a id="pl.8.8"></a><var>8.8</var><br />
                  		
               </td>
               <td align="left" valign="bottom">Michelle L. Fischbach<br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom"></td>
            </tr>
            <tr>
               <td><a id="pl.8.9"></a><var>8.9</var><br />
                  		
               </td>
               <td align="left" valign="bottom">House Conferees:<span width="2em"></span>(Signed)<br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom"></td>
            </tr>
            <tr>
               <td><a id="pl.8.10"></a><var>8.10</var><br />
                  		
               </td>
               <td align="left" valign="bottom"><span>
                     							.....
                     						</span><br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom"><span>
                     							.....
                     						</span><br />
                  		
               </td>
            </tr>
            <tr>
               <td><a id="pl.8.11"></a><var>8.11</var><br />
                  		
               </td>
               <td align="left" valign="bottom">Karen Clark<br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom">Carolyn Laine<br />
                  		
               </td>
            </tr>
            <tr>
               <td><a id="pl.8.12"></a><var>8.12</var><br />
                  		
               </td>
               <td align="left" valign="bottom"><span>
                     							.....
                     						</span><br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom"><span>
                     							.....
                     						</span><br />
                  		
               </td>
            </tr>
            <tr>
               <td><a id="pl.8.13"></a><var>8.13</var><br />
                  		
               </td>
               <td align="left" valign="bottom">Paul Thissen<br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom">Shelley Madore<br />
                  		
               </td>
            </tr>
            <tr>
               <td><a id="pl.8.14"></a><var>8.14</var><br />
                  		
               </td>
               <td align="left" valign="bottom"><span>
                     							.....
                     						</span><br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom"></td>
            </tr>
            <tr>
               <td><a id="pl.8.15"></a><var>8.15</var><br />
                  		
               </td>
               <td align="left" valign="bottom">Jim Abeler<br />
                  		
               </td>
               <td align="left" valign="bottom"></td>
               <td align="left" valign="bottom"></td>
            </tr>
         </table>
      </div>